Learn how GA4GH helps expand responsible genomic data use to benefit human health.
Learn how GA4GH helps expand responsible genomic data use to benefit human health.
Our Strategic Road Map defines strategies, standards, and policy frameworks to support responsible global use of genomic and related health data.
Discover how a meeting of 50 leaders in genomics and medicine led to an alliance uniting more than 5,000 individuals and organisations to benefit human health.
GA4GH Inc. is a not-for-profit organisation that supports the global GA4GH community.
To guide our collaborative, globe-spanning alliance, GA4GH relies on a Standards Steering Committee and an Executive Committee.
The Funders Forum brings together organisations that offer both financial support and strategic guidance.
The EDI Advisory Group responds to issues raised in the GA4GH community, finding equitable, inclusive ways to build products that benefit diverse groups.
Distributed across four Host Institutions, our staff team supports the mission and operations of GA4GH.
Curious who we are? Meet the people and organisations across six continents who make up GA4GH.
More than 500 organisations connected to genomics — in healthcare, research, patient advocacy, industry, and beyond — have signed onto the mission and vision of GA4GH as Organisational Members.
These core Organisational Members are genomic data initiatives that have committed resources to guide GA4GH work and pilot our products.
This subset of Organisational Members whose networks or infrastructure align with GA4GH priorities has made a long-term commitment to engaging with our community.
Local and national organisations assign experts to spend at least 30% of their time building GA4GH products.
Anyone working in genomics and related fields is invited to participate in our inclusive community by creating and using new products.
Wondering what GA4GH does? Learn how we find and overcome challenges to expanding responsible genomic data use for the benefit of human health.
Study Groups define needs. Participants survey the landscape of the genomics and health community and determine whether GA4GH can help.
Work Streams create products. Community members join together to develop technical standards, policy frameworks, and policy tools that overcome hurdles to international genomic data use.
GIF solves problems. Organisations in the forum pilot GA4GH products in real-world situations. Along the way, they troubleshoot products, suggest updates, and flag additional needs.
NIF finds challenges and opportunities in genomics at a global scale. National programmes meet to share best practices, avoid incompatabilities, and help translate genomics into benefits for human health.
Communities of Interest find challenges and opportunities in areas such as rare disease, cancer, and infectious disease. Participants pinpoint real-world problems that would benefit from broad data use.
See all our products — always free and open-source. Do you work on cloud genomics, data discovery, user access, data security or regulatory policy and ethics? Need to represent genomic, phenotypic, or clinical data? We’ve got a solution for you.
All GA4GH standards, frameworks, and tools follow the Product Development and Approval Process before being officially adopted.
Learn how other organisations have implemented GA4GH products to solve real-world problems.
Help us transform the future of genomic data use! See how GA4GH can benefit you — whether you’re using our products, writing our standards, subscribing to a newsletter, or more.
Help create new global standards and frameworks for responsible genomic data use.
Align your organisation with the GA4GH mission and vision.
Solve your real-world data problems with support from this valuable network of global institutions.
Work with like-minded groups committed to better data use in areas like rare disease, cancer, and infectious disease.
Share your thoughts on all GA4GH products currently open for public comment.
Solve real problems by aligning your organisation with the world’s genomics standards. We offer software dvelopers both customisable and out-of-the-box solutions to help you get started.
Learn more about upcoming GA4GH events. See reports and recordings from our past events.
Speak directly to the global genomics and health community while supporting GA4GH strategy.
Be the first to hear about the latest GA4GH products, upcoming meetings, new initiatives, and more.
Questions? We would love to hear from you.
Read news, stories, and insights from the forefront of genomic and clinical data use.
Attend an upcoming GA4GH event, or view meeting reports from past events.
See new projects, updates, and calls for support from the Work Streams.
Read academic papers coauthored by GA4GH contributors.
Listen to our podcast OmicsXchange, featuring discussions from leaders in the world of genomics, health, and data sharing.
Check out our videos, then subscribe to our YouTube channel for more content.
View the latest GA4GH updates, Genomics and Health News, Implementation Notes, GDPR Briefs, and more.
Discover all things GA4GH: explore our news, events, videos, podcasts, announcements, publications, and newsletters.
1 Feb 2021
This brief will discuss, with specific reference to genomic and health-related research, the three ways in which the public interest features in the GDPR: a legal basis, a derogation for the processing of genomic and health data, and a transfer mechanism.
This brief will discuss, with specific reference to genomic and health-related research, the three ways in which the public interest features in the GDPR: a legal basis, a derogation for the processing of genomic and health data, and a transfer mechanism. In none of these cases can a controller invoke the public interest at their plain discretion. It is always up to either EU or national law to specify the public interest. This unfortunately means that, failing a public interest defined in EU law, the contours of the public interest vary across the EU / European Economic Area (EEA).
Controllers may process personal data if “processing is necessary for the performance of a task carried out in the public interest”. Necessity is interpreted under proportionality – the data processed must have a close link to the attainment of the processing’s objectives. National law, for example, may specify that certain entities are able to rely on the public interest legal basis, e.g., public-authority research organizations (UK) or that processing necessary for scientific research may rely on the public interest legal basis but with additional safeguards (Norway). Relying on this legal basis also allows for potentially curtailing the right to object.
Derogation for the processing of genomic and health data
For the processing of genomic and health data, there are two relevant derogations (justifications) that exist. One, where the processing is “necessary for reasons of substantial public interest”. Similar to the public interest basis, proportionality informs the necessity analysis. Beyond this, the public interest must be substantial, which aims to balance the public interest with the risks that processing genomic and health data poses. Distinguishing between a substantial public interest from a “normal” one is not (yet) precisely defined. The substantial public interest derogation is the only justification available for automated decision-making with respect to genomic and health data, other than the data subject’s explicit consent.
Secondly, the processing of genomic and health data may be legitimated where the “processing is necessary for reasons of public interest in the area of public health, such as protecting against serious cross-border threats to health or ensuring high standards of quality and safety of health care and of medicinal products or medical devices”. Such a justification is, of course, very relevant during a pandemic. However, given the article’s public health focus, it is not suitable for general biomedical research in normal circumstances, e.g., basic research into the genetic factors related to breast cancer, unless otherwise specified in national law. Indeed, distinguishing biomedical research from public health monitoring and quality assurance of medicines can be difficult.
In absence of an adequacy decision or other suitable safeguards (e.g., standard contractual clauses), controllers may nevertheless export data out of the EU/EEA where “the transfer is necessary for important reasons of public interest”. Unlike the above examples, the GDPR specifies that either public or private entities may rely on this transfer mechanism. The European Data Protection Board has, for example, stated that scientific research related to the COVID-19 pandemic is one such recognized public interests for the purposes of this transfer mechanism (albeit halfheartedly). In a similar vein, we have seen the French Conseil d’État decline to outright suspend data transfers connected to the Health Data Hub partially on the basis of the public interest in the continued occurrence of the data transfers in relation to the pandemic response.
The public interest under the GDPR is largely a question for national law to determine both which purposes are properly considered to be in the public interest and the additional conditions to which relying on such provisions is subject. A reasonable approach is to then first verify the public interest conditions under applicable national law before relying upon the public interest for data processing.
Relevant GDPR Provisions
Michael Beauvais is an academic associate at McGill University’s Centre of Genomics and Policy.
See all previous briefs.
Please note that GDPR Briefs neither constitute nor should be relied upon as legal advice. Briefs represent a consensus position among Forum Members regarding the current understanding of the GDPR and its implications for genomic and health-related research. As such, they are no substitute for legal advice from a licensed practitioner in your jurisdiction.